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Abstract
Background & Aims—Liver biopsy, the current clinical gold standard for assessment of
fibrosis, is invasive and has sampling errors, and is not optimal for screening, monitoring, or
clinical decision-making. Fibrosis is characterized by excessive accumulation of extracellular
matrix proteins including type I collagen. We hypothesize that molecular magnetic resonance
imaging (MRI) with a probe targeted to type I collagen could provide a direct and non-invasive
method for assessment of fibrosis.
Methods—Liver fibrosis was generated in rats with diethylnitrosamine and in mice with carbon
tetrachloride. Animals were imaged prior to and immediately following i.v. administration of
either collagen-targeted probe EP-3533 or non-targeted control Gd-DTPA. Magnetic resonance
(MR) signal wash-out characteristics were evaluated from T1 maps and T1-weighted images.
Liver tissue was subjected to pathologic scoring of fibrosis and analyzed for gadolinium and
hydroxyproline.
Results—EP-3533 enhanced MR showed greater signal intensity on delayed imaging
(normalized signal enhancement mice: control = 0.39±0.04, fibrotic = 0.55±0.03, p <0.01) and
slower signal washout in fibrotic liver compared to controls (liver t1/2 = 51.3±3.6 vs 42.0±2.5 min,
p <0.05 and 54.5±1.9 vs 44.1±2.9 min, p <0.01 for fibrotic vs controls in rat and mouse models,
respectively). Gd-DTPA enhanced MR could not distinguish fibrotic from control animals.
EP-3533 gadolinium concentration in liver showed strong positive correlations with
hydroxyproline levels (r = 0.74 (rats), r = 0.77 (mice)) and with Ishak scoring (r = 0.84 (rats), r =
0.79 (mice)).
Conclusion—Molecular MRI of liver fibrosis with a collagen-specific probe identifies fibrotic
tissue in two rodent models of disease.
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Introduction
The liver possesses a unique ability to regenerate from a variety of injuries. Depending on
the extent and duration of the injury, the healing processes may result in scarring (fibrosis)
of the liver parenchyma. At the microscopic level this is observed as an accumulation of
extracellular matrix (ECM) rich in fibrillar collagen, mainly types I and III [1]. Long-lasting,
chronic insults such as hepatitis B or C virus infections, obesity, diabetes, alcohol abuse and
other toxic insults all trigger cellular and molecular events that lead to liver fibrosis [2, 3].
The progression is typically slow and it may take decades to accumulate significant fibrosis
in the liver. However, untreated fibrosis is likely to further progress into cirrhosis, which
imposes a high risk of hepatocellular carcinoma and/or liver failure [4, 5]. Rising levels of
obesity and diabetes, the spread of hepatitis B and C infections, and other factors have put
millions of people worldwide in danger of developing cirrhosis [6–8].
Liver fibrosis is currently recognized as a dynamic process with a high potential for partial
or complete resolution, provided that the underlying cause of the disease is suppressed or
removed [1, 9]. One key element in an efficient treatment is a reliable diagnostic method
that allows accurate staging of fibrosis to follow disease progression or response to therapy.
Liver biopsy is the gold standard for staging of liver fibrosis [10]. However, it remains an
imperfect method with appreciable sampling error [11, 12], high inter-observer variability,
and is associated with risk of complications: hospitalization is required in 1 – 5 % of cases
and mortality rate is between 0.01 and 0.1 % [13, 14]. Liver biopsy is also an invasive and
painful procedure and repeated tests are often encountered with low patient compliance.
Therefore, there is an urgent need for a reliable diagnostic method for non-invasive
assessment of liver fibrosis [10, 15–18]. Several methods based on serum biomarkers have
been reported that can identify fibrosis, however these are generally unreliable when it
comes to staging of the disease [10]. Transient elastography [19–22] and magnetic
resonance elastography [23–26] are methods that measure stiffness of the liver associated
with fibrosis. Both methods reliably detect moderate and advanced fibrosis but diagnostic
accuracy is lower for milder stages of disease and test performance may be low in patients
with ascites or morbid obesity [19].
Over-expression of collagen is a hallmark of liver fibrosis. Here we hypothesized that
molecular magnetic resonance imaging (MRI) with a probe targeted to type I collagen could
provide a non-invasive method for assessment of fibrosis. EP-3533 is a gadolinium-based
probe designed to specifically target type I collagen [27] that has previously demonstrated
its utility in MRI of cardiac fibrosis [28]. The goal of this study was to assess the feasibility
of EP-3533 to quantify liver collagen and determine whether collagen targeted MRI has the
potential to act as a non-invasive measure of liver fibrosis.
Materials and methods
Animal models
All experiments were performed in accordance with the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the institution’s animal care and use committee.
Male Wistar rats (Charles River Laboratories, Wilmington, MA) were given weekly
intraperitoneal injections of 100 mg/kg diethylnitrosamine (DEN; Sigma, St. Louis, MO) for
4 weeks (n=5). Control animals received PBS (n=4). Strain A/J male mice (Jackson
Polasek et al. Page 2
J Hepatol. Author manuscript; available in PMC 2013 September 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tLaboratories, Bar Harbor, ME) were administered 0.1 mL of a 40% solution of carbon
tetrachloride (CCl4; Sigma) in olive oil by oral gavage three times a week for 20 weeks
(n=8); age matched controls received only pure olive oil (n=4), or no vehicle (n=6). Animals
from both models were imaged one week after the last injection to avoid acute effects of
DEN or CCl4.
Probes
EP-3533 comprises a ten amino acid cyclic peptide conjugated to three gadolinium moieties,
and was synthesized as previously reported [27]. The peptide confers affinity for type I
collagen (Kd=1.8 μM) and the gadolinium moieties provide strong signal enhancement
(relaxivity = 16.2 mM−1s−1 (5.4 per Gd ion) at 4.7T) [27, 28]. The commercial extracellular
contrast agent gadopentetate dimeglumine (Gd-DTPA, relaxivity = 3.8 mM−1s−1 at 4.7T)
was used as a control [29].
MR imaging and analysis
Animals were anesthetized with isoflurane (1–2%) and placed in a specially designed cradle
with body temperature maintained at 37 °C. The tail vein was cannulated for intravenous
(i.v.) delivery of the contrast agent while the animal was positioned in the scanner. Imaging
was performed at 4.7 T using a small bore animal scanner with a custom-built volume coil.
Doses of the contrast agents were chosen to yield similar signal enhancement based on
relaxivity: 100 μmol/kg (Gd-DTPA) and 20 μmol/kg (EP-3533).
The imaging paradigm was similar for rats and mice. A series of baseline images were
acquired, a bolus of Gd-DTPA was administered i.v. and the imaging was repeated for a
period of 60 minutes post injection. Animals were then returned to their cages and imaged
again 24 hrs (mice) or 48 hrs (rats) later. In the second imaging session, baseline images
were again acquired followed by bolus injection of EP-3533, and imaging was repeated for
60 minutes. Following the second imaging session, animals were euthanized (120 minutes
post injection for rats, 80 minutes post injection for mice), and liver and other tissues were
removed for further analysis.
The imaging protocol involved a T1-mapping sequence (RARE inversion recovery (IR), TR/
TE=3200ms/4ms, matrix=128×128, 7 or 8 inversion times from 7 to 3000 ms, single slice (2
mm for rats, 1 mm for mice), RARE factor 8) that was performed prior to and at 5 or 6 time
points out to 60 min post injection. These sequences were alternated with a T1-weighted
sequence (rats: IR-RARE with inversion time chosen to null the liver signal at baseline, TR/
TE=3200ms/4ms, matrix=128×128, three 2 mm slices, 2 averages, RARE factor 8,
acquisition time = 1.9 min; for mice: gradient echo (TR/TE/flip angle =50ms/1.92ms/35°,
matrix=72×72 interpolated to 128×128, five 1mm thick slices). For the mouse studies an
additional dynamic contrast enhanced (DCE) study was added. The same gradient echo
sequence was run from 1.5 min pre- to 4.5 min post-injection with 3.6s temporal resolution.
FOV=7.2×7.2 cm for rats and 3.6×3.6 cm for mice.
T1 was quantified from a 3 parameter fit of the dependence of liver signal intensity (SI) on
inversion time (TI) using Microsoft Excel with Solver software, equation 1.
(1)
Here TR is the repetition time, SI0 is signal intensity at full recovery, and A is a
preexponential factor. T1, SI0, and A were iteratively varied to fit the observed data.
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T1,pre) with time, assuming a mono-exponential decay.
The DCE data were normalized to maximum enhancement (as 100%) to compare curves
across animals.
Tissue analysis
Formalin-fixed samples were embedded in paraffin, cut into 5 μm-thick sections and stained
with Masson’s trichrome (rats) or Sirius red (mice) according to standard procedures.
Trichrome and Sirius red stained sections were analyzed to score the amount of liver disease
according to the method of Ishak [30]. Additional sections were stained with an antibody
specific for collagen type I (Abcam, Cambridge, MA) with detection by an appropriate
secondary antibody according to the manufacturer’s instructions. All slides underwent
blinded review by a board certified pathologist with expertise in gastrointestinal and hepatic
malignancies. Hydroxyproline in tissue was quantified by HPLC analysis using a reported
method [31]. Gadolinium was quantified in tissue acid digests by inductively coupled
plasma-mass spectrometry (ICP-MS) using dysprosium as an internal standard.
Hydroxyproline and gadolinium are expressed as amounts per wet weight of tissue.
Gadolinium concentrations in the mouse livers were normalized to the gadolinium
concentration in blood to compensate for variations in the injected doses.
Real-time PCR
Real-time PCR was performed on liver samples from a separate set of animals that were not
imaged but received the exact same treatment as the imaged animals. Total RNA was
extracted from liver tissue using TRIzol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions and subsequently treated with DNase I (Promega, Madison, WI).
250 ng of total RNA from each sample was used to create cDNA by single strand reverse
transcription (SuperScript III First-Strand Synthesis SuperMix for qRT-PCR; Invitrogen).
Expression of α1(I) procollagen mRNA was analyzed by quantitative reverse transcription-
PCR (LightCycler; Roche Diagnostics Corporation, Indianapolis, IN). mRNA expression
was normalized to the expression of β-actin. Primer sequences are as follows: α1(I)
procollagen forward TGCTGCCTTTTCTGTTCCTT and reverse
AAGGTGCTGGGTAGGGAAGT, and β-actin forward AGCCATGTACGTAGCCATCC
and reverse CTCTCAGCTGTGGTGGTGAA. All reactions were performed in duplicate
and the experiment was repeated to ensure reproducible results.
Statistics
All data are shown as mean ± SEM. Differences between two groups were tested with
unpaired Student’s t-Test with p <0.05 considered as significant.
Results
Characterization of animal models
Weekly treatment of rats with 100 mg/kg of DEN resulted in moderate to advanced fibrosis
(individual Ishak scores 3–6) after 4 weeks. Morphological changes in the livers of DEN-
treated animals were readily apparent (Fig. S1). Masson’s trichrome staining revealed
multiple portal fibrotic expansions with bridging fibrosis in livers of DEN-treated rats (Fig.
1A). Livers from control animals showed no noticeable fibrosis. Specific staining for
collagen type I confirmed significant deposition in the DEN-treated livers compared to
controls (Fig. 1B). Consistent with this, real-time PCR analysis of liver tissue confirmed that
expression of α1(I) procollagen mRNA was 15-fold higher (p <0.05) in the fibrotic group
compared to controls (Fig. 1C). Quantitative analysis of hydroxyproline (Hyp) was used as a
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tmeasure of the total amount of collagen in tissue. Hydroxyproline levels in fibrotic livers
were on average 2.5-fold higher than in normal livers (control: 208±20, DEN: 528±72 μg
Hyp/g liver, p <0.05, Fig. 1D). As suggested by the error bars in Fig. 1D, inter-individual
variations in hydroxyproline were somewhat higher in the fibrotic group than in the control
group. This is consistent with the variations in Ishak scores and likely it is a result of
individual sensitivities of animals to chronic liver injury. Together, these results demonstrate
that the DEN model successfully induces fibrosis in rat liver accompanied by excessive
deposition of collagen, including type I, in the extracellular matrix.
Similarly, after 20 weeks of oral CCl4 administration in mice, liver fibrosis reached a
moderate to advanced stage (Ishak 3–6). Macroscopic changes in liver appearance were
visible in all fibrotic specimens (Fig. S2A). In some cases we detected hepatocellular
carcinomas that varied in size and quantity. Histology showed numerous portal fibrotic
expansions with bridging in CCl4-treated livers, whereas there was no detectable fibrosis in
the controls (Fig. S2B). Type I collagen immunostaining was markedly increased within the
fibrotic regions of CCl4-treated livers compared to controls (Fig. S2C), and expression of
α1(I) procollagen mRNA was significantly enhanced in fibrotic livers compared to controls
(23-fold, p <0.05, Fig. S2D). Total collagen was increased more than 2-fold in fibrotic livers
as compared to controls (control: 191±5 μg Hyp/g, CCl4: 415±31 μg Hyp/g, p <0.01, Fig.
S2E). Hydroxyproline levels showed a uniform distribution among different lobes of each
liver with a mean relative standard deviation of 15%, confirming that CCl4 treatment leads
to a diffuse fibrotic response throughout the whole liver. In general, the CCl4 mouse model
presented with a fibrosis that was similar to the rat DEN model.
MR imaging of liver fibrosis
We reasoned that immediately after injection, the contrast agent would be in excess in both
the circulation and liver sinusoids relative to the concentration of collagen, and there may be
little or no difference in intensity between fibrotic animals and controls. However as the
contrast agent clears the systemic circulation, we expect to see differences between the
fibrotic and control livers for the collagen-targeted agent EP-3533. In controls, where there
are lower collagen levels, EP-3533 would wash out rapidly, but in fibrotic liver a fraction of
the contrast agent would be bound to the elevated levels of collagen resulting in prolonged
signal enhancement and slower liver signal washout. We would expect untargeted Gd-
DTPA to show no difference in liver signal enhancement and washout between controls and
fibrotic animals. Since the kinetics of liver washout with EP-3533 was unknown, T1
measurements and T1-weighted imaging were performed prior to, and at multiple time
points out to one hour post injection.
Injection of contrast agents (either Gd-DTPA or EP-3533) led to shortening of T1 relaxation
times in both normal and fibrotic livers (Fig. 2A). This resulted in positive signal
enhancement in the liver but little/no change in the stomach or skeletal muscle signal post
injection. To quantify the amount of probe in vivo we determined the T1 values in liver pre-
and post-injection and calculated ΔR1 values. Since ΔR1 is linearly proportional to the
probe concentration in tissue, we could determine the wash-out rate of the probe from liver
(half-life, t1/2) by analyzing changes in ΔR1. EP-3533 t1/2 in fibrotic liver was significantly
longer than in normal liver in both the rat and mouse models (rats: control = 42.0±2.5 min,
DEN = 51.3±3.6 min, p <0.05, Fig. 2B; mice: control = 44.1±2.9 min, CCl4 = 54.5±1.9 min,
p <0.01, Fig. S3B). There was no significant difference in Gd-DTPA half-lives between
control and fibrotic livers in mice or rats (rats: control = 24.7±3.4 min, DEN = 20.7±8.0
min, p = 0.33, Fig. 2C; mice: control = 19.3±3.5 min, CCl4 = 14.6±0.8 min, p = 0.14, Fig.
S3C). Baseline T1 values could not distinguish fibrosis in either model (rats: control =
785±58 ms, DEN = 803±35 ms, p = 0.40; mice: control = 971±18 ms, CCl4 = 990±23, p =
0.26).
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tIn the initial rat study, we noted that although the t1/2 of EP-3533 in the fibrotic livers was
significantly longer than in control livers, single measures of signal change like ΔR1 were
not significantly different between the two groups. This was traced to the small sample size,
but also to experimental variability in the injected dose volume. As a result, the peak signal
enhancement varied. For the mouse study, the protocol was expanded to include a dynamic
study that allowed us to examine the signal enhancement in liver immediately after injection
of the contrast agent, and to precisely measure peak enhancement. After EP-3533 injection,
the CCl4-treated mice and the controls showed distinct differences in liver signal
enhancement as demonstrated in Figure 3. The maximum enhancement was notably shifted
towards later time points in the CCl4 group compared to controls (time-to-peak values,
control: 27.2±5.5 s, CCl4: 93.0±17.1 s, p <0.01, Fig. 3A). After the initial liver
enhancement, the two groups of animals quickly separated with respect to their signal
enhancement values, with the CCl4 group showing slower signal washout resulting in higher
signal enhancement at later time points (Fig. 3B). For example at 55 minutes post injection,
the MR signal intensity in fibrotic mice was 41% higher than in the controls (control:
0.39±0.04, CCl4: 0.55±0.03, p <0.01). Gd-DTPA enhanced MRI showed no significant
difference between the groups in terms of liver uptake (time-to-peak values, control:
27.0±4.3 s, CCl4: 33.0±2.5 s, p = 0.14, Fig. 3C), or wash-out (Fig. 3D).
The concentration of probe in rat liver was determined by elemental analysis ex vivo at 120
min after injection of EP-3533. The dose retained at this time point was on average 1.7-
times higher in fibrotic livers compared to controls (control: 0.50±0.03 %ID/g, DEN:
0.82±0.06 %ID/g, p <0.001, Fig. 2D; %ID/g = percent of injected dose per gram liver). In
mice, at 80 min after EP-3533 injection the liver/blood ratio in fibrotic animals was 1.5-
times higher than in control animals (p <0.01, Fig. S3D). Analysis of mouse or rat liver
either 24 or 48 hrs post Gd-DTPA confirmed that negligible residual Gd remained at this
timepoint, in agreement with literature [32].
Correlation of MRI biomarkers with ex vivo analyses
In both animal models there were marked differences between fibrotic liver and normal liver
in terms of EP-3533 half-lives and ex vivo hydroxyproline and gadolinium concentrations.
We further investigated correlations between the ex vivo data and the imaging results. First,
we validated that ΔR1 can serve as a reliable measure of EP-3533 concentration in vivo.
Plots of the last measured ΔR1 vs. ex vivo gadolinium concentration showed very strong
linear dependence in the CCl4 mouse model (r = 0.90, Fig. 4A; rats: r = 0.96, data not
shown). This allowed us to estimate the relaxivity of EP-3533 in mouse liver as 17.1
mM−1s−1 and 16.2 mM−1s−1 in rat liver (4.7 T, 37 °C).
Next, we compared hydroxyproline and gadolinium concentrations in liver tissue and found
a strong positive correlation in both animal models (mice: r = 0.77, Fig. 4B; rats: r= 0.74,
data not shown). This strong association between collagen and gadolinium suggests that the
higher retention of EP-3533 in fibrotic liver is likely caused by binding to over-expressed
collagen. The half-life of EP-3533 in the liver as assessed by MRI showed moderately
strong correlations with the total collagen (hydroxyproline) in both models (mice: r = 0.61,
Fig. 4C; rats: r = 0.58, data not shown).
The basis of our hypothesis is that total liver collagen concentration correlates with the
extent of fibrosis, and thus MR imaging of collagen is a direct measure of extent of fibrosis.
Total collagen as measured by hydroxyproline analysis correlated well with the Ishak score
(mice: r = 0.89, Fig. 4D; rats: r = 0.89), confirming that increasing fibrosis is associated with
increased total collagen. There was also a strong positive correlation between gadolinium
concentration and Ishak score (mice: r = 0.79, Fig. 4E; rats: r = 0.84, data not shown), or
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demonstrating the feasibility of EP-3533 to quantify fibrosis.
Discussion
Liver fibrosis and its end-stage, cirrhosis, represent the final common pathway of virtually
all chronic liver diseases [2]. While fibrosis can be identified and quantified using biopsy,
repeated biopsy is not a practical solution for monitoring disease progression or response to
therapy. Numerous noninvasive but indirect approaches have been taken to stage fibrosis.
Blood biomarker panels, elastography, and certain MRI measurements (e.g. apparent
diffusion coefficient) correlate with extent of fibrosis. However because of their indirect
relationship to fibrosis, the readouts in these techniques can be altered by factors other than
fibrosis. In theory, a direct measure of fibrosis should be more accurate than these
correlative approaches.
In liver biopsy, collagen deposition is assessed histologically by staining (e.g. Masson’s
trichrome). Stained sections from liver biopsies can be semi-quantitatively scored, for
example by the criteria of Ishak [30]. By analogy, we reasoned that molecular imaging of
collagen would represent a direct and objective measure of fibrosis. The MRI probe
EP-3533 was derived from a phage display screen against type I collagen and was
previously shown to be effective and specific for identifying cardiac fibrosis in myocardial
scar [28].
Liver MRI following EP-3533 administration showed slower signal washout from fibrotic
animals compared to controls. This difference in t1/2 led to stronger signal enhancement in
fibrotic animals compared to controls at later time points. On the other hand, baseline
imaging or Gd-DTPA enhanced MRI could not distinguish fibrotic animals from controls.
Supportive of these findings were ex vivo analyses that showed strong correlations between
probe and collagen concentrations. Similar results were observed in both the rat DEN model
and the mouse CCl4 model suggesting the utility of molecular MR imaging of collagen for
visualizing fibrosis.
MRI is a useful tool for characterizing liver disease. It is noninvasive, has deep tissue
penetration, high spatial resolution, and does not involve ionizing radiation. The absence of
ionizing radiation is particularly relevant in monitoring chronic disease where the patient
may undergo numerous scans over a period of years. A further benefit of MRI is the ability
to examine the whole organ compared to biopsy where only a small fraction of the organ is
sampled.
MRI has been extensively investigated as a tool for detection of liver fibrosis [33, 34].
Measures of native MRI contrast have been evaluated in the context of fibrosis, including
relaxation in the rotating frame (T1ρ) [26], magnetization transfer [35], and apparent
diffusion coefficient (ADC) [36, 37]. Contrast-enhanced techniques utilizing clinically
approved MR contrast agents have been reported as well [38–40]. Common to these
approaches is that the imaging biomarkers are related to fibrosis rather indirectly and may be
affected by other factors such as inflammation, liver perfusion and loss of hepatocyte
function. The molecular imaging approach described here could be complementary to these
existing MR techniques in order to bring more specificity with respect to the fibrotic
component of the disease. We also note that MR can be used to quantify hepatic fat [41],
and one can envision an MR protocol that reports on levels of collagen and fat.
While we have demonstrated the feasibility of collagen-targeted molecular imaging for
identification of fibrosis, there are some limitations to the current study. First, the study was
not powered to address the question of whether EP-3533 enhanced MRI could stage fibrosis.
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varying fibrosis with Ishak scores ranging from 3 to 6. The Ishak score represents
pathological analysis on a very small sample of the liver, while the MR measurement is
averaged over a large cross-section of the liver so there may be some discordance between
these two measures. Future studies should be powered to examine the efficacy of the
contrast agent over a range of Ishak scores, and the intrahepatic variability in Ishak score
should be assessed. Second, the dose of EP-3533 used was not optimized and the sensitivity
of the technique may be increased through dose optimization. Finally, our studies were
performed using a high field (4.7T) small animal scanner. The relaxivity (MR efficiency) of
EP-3533 is 3-fold lower at 4.7T compared to the common clinical field strength of 1.5T
[27]. Thus the sensitivity of the probe to detect changes in liver collagen concentrations may
be much higher when measured with a clinical MR scanner. Future work will address these
questions of experimental optimization and fibrosis staging.
In conclusion, we demonstrate that MRI with a type I collagen-targeted probe can
distinguish liver fibrosis in two animal models of disease. This molecular MR imaging
technique, alone or in combination with other MRI techniques, offers the potential of
directly imaging collagen and staging liver fibrosis.
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tFig. 1. Characterization of fibrosis and collagen deposition in the rat DEN model
(A) Masson’s trichrome staining reveals numerous portal fibrotic expansions in the DEN
sample corresponding to advanced fibrosis, Ishak 5 in this example. There is no detectable
fibrosis in the control sample. (B) Immunostaining for type I collagen in liver shows rich
staining in the DEN treated animals but is absent in the controls. (C) Expression of liver
α1(I) procollagen mRNA was 15-fold higher (* p <0.05) in the DEN treated group
compared to controls. (D) Total liver collagen (as hydroxyproline) is 2.5-fold higher in DEN
treated animals compared to controls (* p <0.05). Box plots in Panels (C) and (D) illustrate
median (line inside box), interquartile range (box), and minimal and maximal (lines
extending above and below box) values.
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tFig. 2. MR imaging of liver fibrosis in the rat DEN model
(A) Inversion recovery MRI (TR/TE/TI=3200ms/4ms/507ms) of rat liver before and 40 min
after injection of 20 μmol/kg EP-3533; S = stomach, L = liver. The inversion time was
chosen to minimize liver signal prior to probe injection. Post injection there is higher signal
in the liver of the DEN treated animal compared to the control. Differences in baseline
stomach signal are due to the absence/presence of chow which shortens stomach T1 [42].
(B) EP-3533 was retained longer in fibrotic livers than in controls (* p <0.05), while (C) the
half-life of Gd-DTPA in the liver did not statistically differ between DEN and control
groups. (D) Ex vivo analysis of EP-3533 (as gadolinium) at 120 min post injection showed
70% higher gadolinium levels in the DEN group compared to controls (** p <0.01).
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tFig. 3. Dynamic MR enhancement of the liver in CCl4 treated and control mice
Dynamic MRI (TR/TE/flip angle=50ms/1.92ms/35°) after injection of either collagen-
binding EP-3533 or non-specific Gd-DTPA probe normalized to peak signal enhancement.
(A, C) Expansion of first 4.5 min after injection showing that with EP-3533 (A), the peak
enhancement appears later and the wash-out is slower in the CCl4 group compared to
control, but Gd-DTPA (C) shows no noticeable difference between the control and fibrotic
groups. (B, D) Complete signal enhancement profiles out to 60 min post injection. EP-3533
(B) shows slower liver wash-out from CCl4 animals compared to controls resulting into
higher relative signal enhancement at later time points. Gd-DTPA (D) does not show
significant differences between the two groups.
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tFig. 4. Correlations between MRI and ex vivo analyses
Open squares: controls, filled squares: CCl4 treated animals. (A) Gadolinium in liver at 80
min after EP-3533 injection correlates linearly with relaxation rate enhancement (ΔR1)
observed at 60 min. (B) Gadolinium (EP-3533) liver:blood ratios correlate with
hydroxyproline (total collagen), showing an association of the probe with increased collagen
levels. (C) Half-life of EP-3533 in the liver as determined by MRI correlates with total
collagen, showing the feasibility of molecular MR imaging to detect fibrosis. (D) Increasing
stage of fibrosis (Ishak score) is well reflected in the increase of hydroxyproline
concentration in tissue. (E) Probe uptake into liver (gadolinium liver:blood) increases with
increasing stage of fibrosis.
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